Description
Olmutinib is an inhibitor of EGFR. It is selective for mutant forms of EGFR, leading to cell death of EGFR-expressing tumor cells. Olmutinib reverses ABCG2-mediated multidrug resistance in cancer cells.
Olmutinib
Product ID O456505
Cas No. 1353550-13-6
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1353550-13-6 |
|---|---|
| Purity | ≥98% |
| Formula | C26H26N6O2S |
| Formula Wt. | 486.59 |
| Chemical Name | Olmutinib |
| IUPAC Name | N-{3-[(2-{[4-(4-Methyl-1-piperazinyl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}acrylamide |
| Synonym | HM61713, BI-1482694 |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Zhang W., Fan Y., et al. Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells. Front Pharmacol. 9:1097 (2018). PMID: 30356705.
Noh Y., Yoon S., et al. A Safety, Pharmacokinetic, Pharmacogenomic and Population Pharmacokinetic Analysis of the Third-Generation EGFR TKI, Olmutinib (HM61713), After Single Oral Administration in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2019. PMID: 31125491.